| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种制备二氧化硫脲的新方法 | CN200810014206.4 | 2008-01-25 | CN101372750A | 2009-02-25 | 任君合 |
| 本发明属于化工领域中一种生产制备二氧化硫脲的新方法。发明采用电解方法，通过电解水产生的氧原子，将硫脲氧化为二氧化硫脲。硫脲和固体硫酸氢铵的重量比为10∶1～20∶1，加入水使硫脲溶液达到饱和，共同加入普通电解槽中；若pH＞5，用H2SO4调节pH值，使电解槽中溶液pH值为3～5；通以直流电，电压3～5伏；在电解过程中生成二氧化硫脲，达到饱和溶液时继续反应，析出二氧化硫脲，充分反应2～10小时；将析出的二氧化硫脲过滤后自然晾干；将反应后的电解质溶液再次溶解硫脲循环利用。有益效果是克服了常规生产方法造成大量的水污染及产品流失的缺陷。使用硫酸氢铵电解质溶液具有成本便宜，溶解度大，电解效果好等优点。 | ||||||
| 2 | 治疗炎症、糖尿病以及相关疾病的化合物 | CN200480018500.2 | 2004-05-07 | CN100522151C | 2009-08-05 | P·内奥吉; D·戴伊; J·C·富勒; L·陈; T-K·李 |
| 本发明涉及新的酰脲、氨基甲酸酯、硫代氨基甲酸酯及相关化合物，所述化合物在抑制培养细胞中细胞因子介导的炎症反应中、在改善关节炎动物模型的骨破坏中和在降低II型糖尿病动物模型的血糖含量中是有效的。还公开了所述化合物用于各种治疗，包括治疗糖尿病、胰岛素抗药性、炎症、炎性疾病、免疫疾病和癌症的用途。 | ||||||
| 3 | 一种制备二氧化硫脲的方法 | CN200810014206.4 | 2008-01-25 | CN101372750B | 2011-06-01 | 任君合 |
| 本发明属于化工领域中一种生产制备二氧化硫脲的新方法。本发明采用电解方法，通过电解水产生的氧原子，将硫脲氧化为二氧化硫脲。硫脲和固体硫酸氢铵的重量比为10∶1～20∶1，加入水使硫脲溶液达到饱和，共同加入普通电解槽中；若pH＞5，用H2SO4调节pH值，使电解槽中溶液pH值为3～5；通以直流电，电压3～5伏；在电解过程中生成二氧化硫脲，达到饱和溶液时继续反应，析出二氧化硫脲，充分反应2～10小时；将析出的二氧化硫脲过滤后自然晾干；将反应后的电解质溶液再次溶解硫脲循环利用。有益效果是克服了常规生产方法造成大量的水污染及产品流失的缺陷。使用硫酸氢铵电解质溶液具有成本便宜，溶解度大，电解效果好等优点。 | ||||||
| 4 | 治疗炎症、糖尿病以及相关疾病的化合物 | CN200480018500.2 | 2004-05-07 | CN1812779A | 2006-08-02 | P·内奥吉; D·戴伊; J·C·富勒; L·陈; T-K·李 |
| 本发明涉及新的酰脲、氨基甲酸酯、硫代氨基甲酸酯及相关化合物，所述化合物在抑制培养细胞中细胞因子介导的炎症反应中、在改善关节炎动物模型的骨破坏中和在降低II型糖尿病动物模型的血糖含量中是有效的。还公开了所述化合物用于各种治疗，包括治疗糖尿病、胰岛素抗药性、炎症、炎性疾病、免疫疾病和癌症的用途。 | ||||||
| 5 | Substituted thiophenesulfonylurea and-thiourea, their production, their use as medicament or diagnostic, and medicament containing them | JP1575996 | 1996-01-31 | JPH08253471A | 1996-10-01 | HAINRIHI ENGURAATO; IENSU HARUTOUNGU; PEETAA KURAUZE; DEIITAA MANIA; HAINTSU GEEGERAIN; YOOAHIMU KAIZAA |
| PROBLEM TO BE SOLVED: To obtain the subject compounds showing pharmacological effects for cardiovascular systems. SOLUTION: The compounds are shown by formula I [R(1) is H, a halogen, alkyl, alkoxy or the like; R(2) is H, methyl or trifluoromethyl; X is O or S; and Y and Z are each H, F, Cl, Br, I, an alkyl or alkoxy] e.g. 2-[2-chloro-2- ethoxybenzoylamino]ethyl]-5-(methylaminocarbonylaminosulfonyl)thiophene. The compound shown by formula I is obtained by reacting an aromatic sulfoneamide shown by formula II with an R(2)-substituted isocyanate of the formula R(2)-N=C=O. The compound shown by formula I is useful for, e.g. treatment of cardiac dysrhythmia, prophylaxis of sudden cardiac death, treatment of cardiac ischemia symptoms, blocking ATP-sensitive potassium channels, and as a medicament to improve cardiac functions after heart transplantation. COPYRIGHT: (C)1996,JPO | ||||||
| 6 | Substituted benzenesulfonylurea and-thiourea, their preparation and their use for pharmaceutical preparation based on the compounds, and mbdicament containing them | JP5263396 | 1996-02-16 | JPH08245556A | 1996-09-24 | ENGLERT HEINRICH; GERLACH UWE; MANIA DIETER; GOEGELEIN HEINZ; KAISER JOACHIM |
| PROBLEM TO BE SOLVED: To obtain the subject compound useful for the treatment of arrhythmia, the prevention of unexpected death caused by arrhythmia, the treatment, etc., of ischemic diseases as medicaments capable of acting on the cardiovascular system. SOLUTION: This substituted benzenesulfonyl(thio) urea is a compound expressed by formula I {R(1) is H, a 1-7C alkyl or the like; R(2) is H, a 1-6C alkyl, a 1-6C alkoxy or the like; R(3) is H, a 1-12C alkyl or the like; R(4) is H, a 1-12C alkyl or the like; R(3) and R(4) together form a (CH 2) 2-8 ring; E is O or S; X is O or S; Y is a [CR(5)R(5')] m; [R(5) and R(5') are each H or a 1-2C alkyl]}, e.g. 3-sulfonylamino-N-methylaminothiocarbonyl-4-methoxyphenyl- N-cyclohexylpropionamide. The compound of formula I is obtained by reacting a sulfonamide of formula II with a R(1)-substituted isocyanate of the formula R(1)-NCO. The compound of formula 7 is also useful as preventive preparations for heart diseases and diseases of heart transplantations or cerebral blood vessels. COPYRIGHT: (C)1996,JPO | ||||||
| 7 | Substituted thiophene sulfonyl urea and - thioureas, processes for their preparation, their use as medicament or diagnostic agents and medicaments containing them | JP1575996 | 1996-01-31 | JP4021949B2 | 2007-12-12 | イエンス・ハルトウング; デイーター・マニア; ハインツ・ゲーゲライン; ハインリヒ・エングラート; ペーター・クラウゼ; ヨーアヒム・カイザー |
| 8 | Substituted benzenesulfonyl ureas and - thioureas, a medicament for use and containing their pharmaceutical formulations based on the preparation and these compounds | JP5263396 | 1996-02-16 | JP3905573B2 | 2007-04-18 | ウーヴエ・ゲルラハ; デイーター・マニア; ハインツ・ゲーゲライン; ハインリヒ・エングラート; ヨーアヒム・カイザー |
| 9 | Il-8 receptor antagonist | JP50344898 | 1997-06-24 | JP2000514049A | 2000-10-24 | ウィドーソン，キャサリン・エル |
| (57)【要約】 本発明は、ケモカイン、インターロイキン−８（ＩＬ−８）により媒介される病状の治療における式(Ｉ)および(II)で示されるフェニル尿素の使用に関する。 (Ｉ)および(II)の記号は、明細書中に定義されている。 | ||||||
| 10 | Indicator composition for detecting sterilization | JP13886591 | 1991-06-11 | JPH04364174A | 1992-12-16 | TAKEMURA KIYOTO; KOBAYASHI OSAO |
| PURPOSE: To obtain the subject composition containing a transition metal compound, sulfur, monoazo dye, organic acid, etc., as active ingredients and capable of corresponding to both of autoclave sterilization and ethylene oxide gas sterilization in medical field. CONSTITUTION: 2-15 pts.wt. transition metal compound (e.g. bismuth oxide) is mixed with 5-30 pts.wt. sulfur or a sulfur compound (e.g. 1,3- diphenyl-2-thiourea), 0.1-3.5 pts.wt. monoazo dye expressed by the formula (R 1 is H, methyl, ethyl or acylamino; R 2 is H, methoxy or ethoxy; R 3 to R 5 are H, OH, nitric acid or 1-4C alkyl) and 1-15 pts.wt. organic acid or metal salt of organic acid (e.g. calcium salicylate). Then, a vehicle for ink is added to the mixture and these components are blended and made into ink by a dispersing machine to prepare the indicator composition. The composition is reacted with both of high pressure steam and ethylene oxide gas to provide the objective indicator having color changing property capable of displaying sterilization state. COPYRIGHT: (C)1992,JPO&Japio | ||||||
| 11 | Use of it as a 3,4-dihydroxy-benzyl-substituted carbonic acid derivatives and anti-oxidant | JP2002503677 | 2001-06-11 | JP2003535915A | 2003-12-02 | ジヨンコツク，ウイリアム; ライ，ヤコブ・ペーター; ラングナー，ローラント |
| (57)【要約】 本発明は、３，４−ジヒドロキシベンジル置換炭酸誘導体、これの製造そしてこれを抗酸化剤またはフリーラジカル捕捉剤、特に細胞および組織の老化を加速させるラジカルおよび反応性酸素化合物の有害な影響からそれらを保護する目的で化粧および薬学用調剤そして食品および嗜好品に入れる抗酸化剤またはフリーラジカル捕捉剤として用いることに関する。 本発明は、更に、本発明の３，４−ジヒドロキシベンジル置換炭酸誘導体を含んで成る化粧および薬学用調剤そして食品および嗜好品にも関する。 | ||||||
| 12 | Sterilization detection indicator composition | JP13886591 | 1991-06-11 | JP3161751B2 | 2001-04-25 | 長生 小林; 清人 竹村 |
| 13 | JPS5213741B2 - | JP5053972 | 1972-05-22 | JPS5213741B2 | 1977-04-16 | |
| 14 | JPS4916435A - | JP5053972 | 1972-05-22 | JPS4916435A | 1974-02-13 | |
| 15 | IL-8 수용체 길항제 | KR1019980710694 | 1997-06-24 | KR1020000022274A | 2000-04-25 | 위도우선,캐써린,엘. |
| PURPOSE: Phenyl ureas is provided which is useful for the treatment of disease states mediated by the chemokine, Interlukin-8(IL-8). CONSTITUTION: A method for treating a chemokine mediated disease comprises administering an effective amount of a compound of formula (I) or (II), or a pharmaceutically acceptable salt thereof. In particular, the chemokine is IL-8, GROα, GROβ, CORγ, NAP-2 or ENA-78. The compound of formula (I) is administered in an amount sufficient to inhibit cytokine function, particularly, the function of IL-8, GROα, GROβ, CORγ, NAP-2 or ENA-78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, to ameliorate the disease state. | ||||||
| 16 | Insecticidal substituted thiourea derivatives | EP07009600.3 | 2007-05-14 | EP1992228A1 | 2008-11-19 | The designation of the inventor has not yet been filed |
The present invention generally relates to specific thiourea derivatives and their use for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to compositions of these pesticidal active thiourea derivatives. Furthermore, the present invention pertains to processes for their preparation and to methods for their use in controlling insects and acarids. |
||||||
| 17 | NOVEL ANTI-ADHESIVE COMPOUNDS AND USES THEREOF | EP02725119 | 2002-03-12 | EP1385821A4 | 2006-03-08 | ALBERTE RANDALL S; SMITH ROBERT D |
| Compounds which exhibit anti-adhesive properties are described. The compounds may be monomers or polymers. Methods for treating receptor mediated diseases are provided using compounds of the invention. Further methods are provided for crop protection, medical devices and anti-fouling. | ||||||
| 18 | IL-8 RECEPTOR ANTAGONISTS | EP97930204 | 1997-06-24 | EP0912505A4 | 2001-10-24 | WIDDOWSON KATHERINE L |
| 19 | 1,4-Dihydropyridin-threonin-Derivate und Verfahren zu ihrer Herstellung | EP89110528.0 | 1989-06-10 | EP0347678B1 | 1997-02-26 | Stoltefuss, Jürgen, DI.; Bechem, Martin, Dr.; Gross, Rainer, Prof.- Dr.; Hebisch, Siegbert, Dr.; Schramm, Matthias, Dr. |
| 20 | Thiourea group IV transition metal catalysts and polymerization systems | US16333049 | 2017-09-13 | US10968297B2 | 2021-04-06 | Arkady L. Krasovskiy; Endre Szuromi |
| Catalyst compositions and polymerization systems include at least one thiourea complex according to Formula (I): MQaX4-a (I) in which M is Ti, Zr, or Hf; a is 1 or 2; each group Q of the thiourea complex is a bidentate thiourea ligand bound to the metal center and having Formula (Ia), Formula (Ib), or Formula (Ic): (Formulas should be inserted here). In Formulas (Ia), (Ib), and (Ic), each group R1, R2, and R3 is independently chosen from alkyl groups or aryl groups; each group Z1 or Z2 is independently chosen from alkylene groups. If a=2, groups R1 of the two groups Q are optionally linked, or groups R3 of the two groups Q are optionally linked. Each X is covalently bonded or coordinated to the metal center and is independently chosen from alkyl groups or halides. The polymerization systems may be configured to copolymerize ethylene and α-olefins. | ||||||
QQ群二维码
意见反馈
意见反馈